Aura Biosciences reports Q1 2023 net loss of $17.5M; FDA backs Phase 3 trial design for choroidal melanoma

Aura Biosciences, Inc.

Cash and marketable securities $173.5M as of March 31, 2023; cash runway into 2025.
Net loss $17.5M for Q1 2023 vs $12.8M in Q1 2022; R&D expense $14.4M (up from $8.3M).
FDA Type C meeting supports global Phase 3 trial (≈100 patients, 2:1:2 randomized) for early-stage choroidal melanoma.
Phase 2 enrollment complete; updated interim data expected 2H 2023; Phase 1 NMIBC data also due 2H 2023.
Appointed Patrick Nealon as SVP, Clinical Development Operations to lead late-stage development.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aura Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $17.5 million.

Period: the quarter ended March 31, 2023
Net income: $17.5 million
Result: reported results

Exact text from the filing

On May 11, 2023, Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.